Plymouth, PL6 5HH, United Kingdom
NCT Number: NCT00751764
Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–45 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy lactating women aged 21 to 45 years inclusive at screening. Women should:
- Be at least 12-weeks postpartum after uncomplicated delivery with a full milk supply established.
- Be willing to discontinue breastfeeding permanently and should be in the process of weaning their infant. Care should be taken to ensure that subjects have not discontinued breastfeeding an infant in order to participate in the study.
- Not plan to breastfeed within 9 months of study drug administration.
- Be willing to fully express breast milk from both breasts during the duration of the milk collection portion of the study. Subjects must be able to express milk from each breast at each pumping session using a breast pump.
- Body mass index in the range of 18 to 35 kg/m2.
Exclusion criteria
- Presence or history of any disorder that may prevent the successful completion of the study.
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Treatment and study plan
Moxidectin
DrugPrimary outcomes
-
Blood samples
Time frame: 4 months
Secondary outcomes
-
Safety based on adverse event monitoring, vital sign measurements, 12-lead ECGs and routine lab tests.
Time frame: 4 months
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.
Important dates
- Study start
- 2008
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Sep 12, 2008
- Registry last updated
- Sep 16, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial
NCT04048304
Infection, Infections
Zurich, Canton of Zurich, Switzerland
View Trial DetailsViscoelastic Coagulation for Early Sepsis Detection
NCT07073456
Cardiovascular Diseases, Embolism and Thrombosis
Chaïdári, Attica, Greece
View Trial DetailsNew Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
NCT00342589
Bacterial Infections and Mycoses, Infection
Bethesda, Maryland, United States
View Trial DetailsPReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT04815876
Genital Diseases, Genital Diseases, Male
Los Angeles, California, United States
View Trial Details